Q-omics provides the consensus-scored NCS1 profile across patient tissues and cancer cell-line models. NCS1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NCS1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, NCS1 protein abundance shows 31,251 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where NCS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCS1 survival associations across molecular data types. NCS1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCS1 RNA expression–survival associations across cancer types. High NCS1 expression shows unfavorable associations in UVM, KIRC, MESO, ACC, BRCA and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NCS1 RNA expression.
This table summarizes NCS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NCS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCS1 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in HNSC, LUAD and LIHC. The HNSC box plot shows higher NCS1 RNA expression in tumor versus normal tissue (log2 FC = +1.567, t-test p < 0.001).
This table shows molecular features associated with NCS1 in patient tissues and cancer cell lines. In patient samples, NCS1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NCS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and PANCREAS.
